Email galleryPricing
Get started
Sign InGet started
Email gallery/Novo Nordisk/Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
Novo Nordisk logoNovo NordiskSee all their emails

Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine

A real announcement email from Novo Nordisk. Captured November 16, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine email from Novo Nordisk screenshot

About this email

Captured November 16, 2026·Announcement

Novo Nordisk shares primary results from the phase 3 STEP Young trial evaluating semaglutide in children aged 6 to under 12 with obesity.

Traditional press release format featuring a top-left company logo, bulleted key findings, formal editorial paragraphs, and structured scientific trial data tables.

Explore similar emails

  • Text Heavy
  • Corporate
  • Light Mode
  • Health, Fitness & Wellness
  • Awareness
  • Newsletter Subscribers
  • Newsletter

Color palette

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.

Solutions

  • Marketers
  • Designers
  • Developers
  • Enterprise
  • Claude
  • ChatGPT
  • Grok Bot

Resources

  • Countdowns
  • Spoof checker
    New
  • BIMI logo
  • Email gallery
  • Tabpass
  • Pricing
  • Docs
  • Blog

Company

  • About Us
  • Brand guidelines
  • Brand kit
  • Careers
  • Support
  • FAQ

Legal

  • Privacy Policy
  • Terms & Conditions
  • Do not sell or share my personal information
  • Copyright Notice & Takedown
  • Data Processing Agreement
  • Acceptable Use

Socials

  • X / Twitter
  • Discord
  • YouTube
  • LinkedIn
MigmaAI
© 2026 MigmaAI, Inc. All rights reserved.
Backed byEWOR Logo DarkEWOR Logo Light
Built with ❤️ in Stockholm & Barcelona